Skip to main content
. 2023 Aug 15;109(11):3602–3608. doi: 10.1097/JS9.0000000000000645

Table 1.

Baseline characteristics of patients included in the studies.

Variables Blumenstein et al., 20228 Corcione et al., 202013 Perlman et al.4 Willson et al.14 Mollmann et al.3 (PorticoTM DS) Mollmann et al.3 (FlexNavTM DS) Möllmann et al.15 Raj R Makkar et al.
Sample size 344 114 57 10 501 500 222 1034
Study design Nonrandomized cohort Observational cohort Observational cohort Observational cohort Observational cohort Observational cohort Prospective, nonrandomized, multicenter study RCT
Age, years (Mean) 82.92 82.4 80.8 82.4 81.7 82.3 83.0 83±7
Female, n (%) 206 (59.9) 70 (61) 47 (82.5) 10 (100%) 320 (63.70%) 307 (61.40%) 165 (74.32%) 395 (52·7%)
NYHA Class III/IV 290 85/1 43 8/0 295 / 32 293/18 166/ 9 229 (60·1%)/43 (11·3%)
STS score 7.7±5.7 8.1 3.2 4.2±2.9 4.2±2.7 5.8±3.3 6·5 ±3·4
Diabetes, n (%) 120 21 20 5 176 182 69 143 (37·5%)
Hypertension, n (%) 308 80 46 440 431 358 (94·0%)
Previous MI, n (%) 37 10 10 68 61 26 55 (14·4%)
Previous stroke, n (%) 31 2 7 53 38 18 29 (7·6%)
Previous peripheral artery disease, n (%) 48 14 1 60 59 18 72 (18·9%)
Previous atrial fibrillation, n (%) 135 20 246 238 85 125 (32·8%)
Mean AVA, cm2 0.6 0.7 0.62 0.71 0.72 0·68±0·17
LVEF,% 59.25 55 58.4 57.3 >20 57·3 (11·5)
Moderate to severe mitral regurgitation, n 5 50 5 1 1 78 (20·5%)
Mean Transaortic gradient, mmHg 42.75 50 41.8 44.5 43.4 42.2 43.3 46·2 (11·2)